替格瑞洛在行PCI治疗的急性心肌梗死患者中的临床疗效和安全性观察

目的：观察替格瑞洛配合PCI治疗急性心肌梗死的临床疗效和安全性,为该药物的临床推广应用提供参考。方法：选取在本院接受替格瑞洛治疗的184例心梗患者为研究组,并选取基线资料相似的184例接受氯比格雷治疗的患者为对照组。对其进行为期6个月的临床疗效跟踪评价,考察两组治疗期间的心肌梗死溶栓（TIMI）、梗死区心肌灌注（TMP）、主要心血管事件（MACE）等指标以及血小板水平的改变。结果：研究组治疗1、3、6个月时的左心室射血分数（LVEF）优于对照组,3、6个月时的左心室舒张末期半径（LVEDD）优于对照组,差异具有统计学意义（P〈0.05）;研究组6个月内的急性血栓发生率方面低于对照组,且差异具有统计学意义（P〈0.05）;研究组治疗1周、1、3、6个月时的血小板水平均高于对照组,差异具有统计学意义（P〈0.05）。结论：替格瑞洛在改善心肌梗死患者的心脏功能方面与氯比格雷相似,且在改善血小板水平和降低急性血栓形成方面有一定优势,值得临床进一步推广和深入研究。

Clinical effect and safety of ticagrelor in patients undergoing PCI treatment for acute myocardial infarction

Objective： To investigate the clinical effects and safety of ticagrelor in patients undergoing PCI treatment for acute myocardial infarction, and to provide a reference for the clinical application of ticagrelor. Methods： A total of 184 patients with acute myocardial infarction （AMI） were enrolled as study group, which were treated with ticagrelor, and 184 patients treated with clopidogrel were selected as control group. Then clinical efficacy indicators including TIMI, TMP, MACE, the platelet levels and the adverse reactions were investigated according to follow up of a period of 6 months. Results： After 1, 3 and 6 months of treatment, the LVEF of the treatment group was better than that in the control group. After 3 and 6 months of treatment, the LVEDD was better than that in the control group （P〈0.05）. The incidence of MACE of study group was significant lower than that of the control group （P〈0.05）. The platelet levels of study group after 1 week,1 month, 3 months and 6 months of treatment was higher than control group, and the difference was statistically significant （P〈0.05）. The incidence of adverse reaction of control group and study group had no a statistically difference （P〉0.05）. Conclusions： Ticagrelor shows similar effects on myocardial infarction and cardiac function of AMI patients as clopidogrel, hut it has better effects on improving the platelet levels and reducing incidence of acute thrombosis, it＇s worthy of further promotion and in-depth research.